HealthDay on MSN4d
FDA Approval Expands Earlier Use of Enhertu for Metastatic Breast CancerThe U.S. Food and Drug Administration has approved Enhertu (trastuzumab deruxtecan) for the treatment of adult pat ...
Astra is due to pay Daiichi US$175 million in milestones after the US approval, the companies said. Enhertu is cleared in the ...
A phase 3 clinical trial has shown that adding a targeted immunotherapy drug to chemotherapy dramatically improved – almost ...
Maintaining treatment with CDK4/6 inhibitors significantly suppresses the growth of breast cancer cells, even after drug resistance has developed, according to new research.
The European Medicines Agency has recommended three new medicines to treat breast and cervical cancer and ...
In a video interview, William K. Oh, MD, director of precision medicine at Yale Cancer Center and Smilow Cancer Hospital discusses the latest breakthroughs in advanced prostate cancer treatment.
Sep. 4, 2024 — A treatment paradox has recently come to light in prostate cancer: blocking testosterone production halts tumor growth in early disease, while elevating the hormone can delay ...
On January 7, 2025, the FDA granted priority review to the new drug application for sunvozertinib (DZD9008), an oral EGFR ...
And we've seen some data that perhaps the hormone therapies ... the question of whether we should be using these drugs during cancer therapy, but rather, patients who have aggressive diabetes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback